
Partial response (PR) N =1
Stable disease (SD) N =30
Progression of disease (PD) N =12
Not assessable N =2
% Change in Target Lessions
50
40
30
20
10
0
-10
-20
-30
-40
-50
Treatment: Fruquintinib+BSC


Stable disease (SD) N =5
Progression of disease (PD) N =17
Not assessable N =1
% Change in Target Lessions
50
40
30
20
10
0
-10
-20
-30
-40
-50
Treatment: Placebo+BSC